There are a variety of cancer IO-based therapies such as targeted antibodies, adoptive cell therapies, checkpoint inhibitors, cytokines, and even vaccines. Many of these therapies can also be used in combination with radiation, chemotherapy, and surgery to enhance their effectiveness. In this newsletter, we will discuss two types of IO therapies, which are engineered to increase cancer killing efficiency. The first is Chimeric Antigen Receptor (CAR) T-cell therapy and a second is Bi-specific T-cell engager antibodies (BiTEs).
CAR T-cell therapy involves collecting the patient’s own immune cells, increasing the immune cell number in the laboratory, and modifying it so it specifically attacks the prostate cancer cell. These modified immune cells are re-introduced into the patient where they seek-out and eliminate cancerous cells.
